What Is VIP? Definition and What Research Reports

VIP in Plain Language

VIP is short for vasoactive intestinal peptide (sometimes written vasoactive intestinal polypeptide). It is a short chain of 28 amino acids that the body makes naturally, mostly in nerve fibres of the gut, lungs, brain and blood vessels, and also in certain immune cells. The name is descriptive rather than branded: it was called "vasoactive" because early work found it relaxed blood vessels, and "intestinal" because it was first isolated from intestinal tissue. Because it is produced by the body and acts as a messenger between cells, VIP is classed as a neuropeptide and a regulatory peptide rather than a drug in its own right.

Outside biology, the same three letters mean "very important person", so search results for "VIP meaning" mix the two entirely unrelated uses. This page covers only the peptide.

What VIP Is in Biochemical and Regulatory Terms

VIP belongs to the secretin–glucagon superfamily of peptides, a group that also includes PACAP (pituitary adenylate cyclase-activating polypeptide), secretin, glucagon and GHRH. Members of this family share structural similarity and often overlap in which receptors they can bind.

Receptors and signalling

VIP signals mainly through two G-protein-coupled receptors, VPAC1 and VPAC2, which are shared with PACAP; activation typically raises intracellular cyclic AMP. Because VPAC receptors are distributed across gut smooth muscle, airway tissue, vascular tissue and lymphocytes, the literature describes VIP as pleiotropic — the same molecule is studied in gastrointestinal physiology, immunology, circadian biology and ophthalmology by different research groups who rarely cite one another.

Stability

Like most short native peptides, VIP is degraded quickly by peptidases in plasma, which is why a substantial share of the published work is not about VIP itself but about how to present or protect it. Researchers have described self-assembling amphiphile micelles built from VIP and reported that the resulting nanostructures altered immunomodulatory activity relative to free peptide in their laboratory systems (2018), and a follow-up study reported that the chemical structure and the hydrophobic domain of the amphiphile influenced that immunomodulatory potentiation (2022).

How the Term Is Used in Peptide Research

"VIP" appears in at least four distinct research literatures, and conflating them is the single most common source of confusion:

• Endocrine oncology. Tumours that oversecrete VIP are a recognised clinical entity, and the term "VIPoma" is used for the pancreatic form.
• Immunology and mucosal biology. VIP is studied as an endogenous anti-inflammatory signal in laboratory models of gut and immune injury.
• Materials and delivery chemistry. VIP sequences are used as building blocks for nanomaterials, or as targets for binding partners such as heparin fragments.
• Comparative and developmental biology. VIP homologues in fish and birds are investigated for their role in immunity and development.

Where the Term Is Misused

Several patterns of misuse recur in non-scientific write-ups:

1. Species substitution. Tilapia, trout and chick-embryo findings are frequently quoted online as though they were human results; the papers themselves reported only their own model systems (2022 tilapia study, 2020 chick embryo study).
2. Case reports read as efficacy data. Reports of VIP-secreting tumours describe what happens when a tumour releases excess VIP; they are not studies of VIP administration and report no benefit.
3. Family blurring. VIP, PACAP and secretin are sometimes treated as interchangeable because they share receptors. They are distinct molecules with distinct literatures.
4. Acronym collision. Searches for "what is VIP" return hospitality and membership content unrelated to the peptide.

Related Terms

What the Published Literature Reports

VIP-secreting tumours

A 2019 review of VIP-secreting tumours summarised how these lesions present and how the clinical literature characterises them, and reported that the hallmark presentation involves profuse secretory diarrhoea with electrolyte disturbance (review, 2019). Individual case reports have described VIP secretion from tumours outside the pancreas: researchers reported a VIP-producing phaeochromocytoma complicated by intracardiac thrombosis (2021 case report) and a further VIP-secreting phaeochromocytoma case accompanied by a review of the prior literature (2022 case report). A separate paediatric report described a VIP-secreting neuroblastoma (2024 case report). These are descriptions of disease states in which endogenous VIP is elevated.

Inflammation and epithelial barrier models

In an experimental model of necrotising enterocolitis, the study reported that VIP decreased inflammation and reduced tight junction disruption compared with untreated controls in that model (2019 experimental study). This was a laboratory model of intestinal injury, and the authors did not report human outcomes.

Binding, inhibition and formulation chemistry

Researchers characterised the binding process between heparin oligosaccharides and VIP and reported that these oligosaccharides acted as VIP inhibitors in their assays (2024 binding study). Work on VIP amphiphile micelles reported that assembling the peptide into micelles changed its immunomodulatory behaviour, with the hydrophobic domain identified as a variable of interest (2018, 2022).

Comparative and developmental research

In fish immunology, one study reported an immunomodulatory role for VIP and ghrelin in rainbow trout (Oncorhynchus mykiss) (2023), and another reported that VIP protected Nile tilapia against Streptococcus agalactiae infection in that species (2022). A separate study examined VIP function in chick embryonic bone development (2020). None of these were human studies.

Ophthalmology

A 2017 review discussed VIP in the context of eye growth regulation and asked whether it might be a candidate agent in myopia research, framing the question as open rather than settled (review, 2017).

VIP Excess in Tumour Case Literature: What Studies Report

The clearest description of what excess VIP looks like comes from the tumour literature rather than from administration studies. The 2019 review reported that VIP-secreting tumours are associated with large-volume watery diarrhoea, hypokalaemia and achlorhydria, the combination described as WDHA syndrome (2019). Case reports added further findings in individual patients, including intracardiac thrombosis alongside a VIP-producing phaeochromocytoma (2021) and a paediatric neuroblastoma presenting with VIP secretion (2024). Because these describe endogenous oversecretion by tumours, researchers did not report them as adverse events of any administered product, and single cases cannot be generalised.

Educational Disclaimer

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or before making any decision related to a medical condition. Nothing here describes a protocol, and no product is offered, endorsed or characterised as safe or effective. Much of the VIP literature summarised above comes from animal models, cell systems or individual case reports, and findings in those settings are not evidence of human outcomes.

References

• Vasoactive Intestinal Peptide-Secreting Tumors: A Review (Pancreas, 2019)
• Vasoactive intestinal peptide producing pheochromocytoma and intracardiac thrombosis (Rare Tumors, 2021)
• Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature (AACE Clinical Case Reports, 2022)
• Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma (Journal of Indian Association of Pediatric Surgeons, 2024)
• Vasoactive intestinal peptide decreases inflammation and tight junction disruption in experimental necrotizing enterocolitis (Journal of Pediatric Surgery, 2019)
• Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization (Current Protein & Peptide Science, 2024)
• Immunomodulatory vasoactive intestinal peptide amphiphile micelles (Biomaterials Science, 2018)
• Vasoactive Intestinal Peptide Amphiphile Micelle Chemical Structure and Hydrophobic Domain Influence Immunomodulatory Potentiation (ACS Applied Bio Materials, 2022)
• Immunomodulatory role of vasoactive intestinal peptide and ghrelin in Oncorhynchus mykiss (Heliyon, 2023)
• Vasoactive Intestinal Peptide (VIP) Protects Nile Tilapia (Oreochromis niloticus) against Streptococcus agalactiae Infection (International Journal of Molecular Sciences, 2022)
• Function study of vasoactive intestinal peptide on chick embryonic bone development (Neuropeptides, 2020)
• Vasoactive intestinal peptide, a promising agent for myopia? (International Journal of Ophthalmology, 2017)